Gd3+-DTPA-DG: novel nanosized dual anticancer and molecular imaging agent by Amanlou, Massoud et al.
© 2011 Amanlou et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2011:6 747–763
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
747
OrIgINAL reseArch
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/IJN.S17648
gd3+-DTPA-Dg: novel nanosized dual anticancer  
and molecular imaging agent
Massoud Amanlou1
seyed Davar siadat4,5
seyed esmaeil sadat 
ebrahimi1
Abass Alavi7
Mohammad reza 
Aghasadeghi2
Mehdi Shafiee Ardestani1,4,6*
saeed shanehsaz2
Masoud ghorbani6
Bita Mehravi8
Mohammad Shafiee Alavidjeh3
Ali Jabbari-Arabzadeh1
Mehdi Abbasi4
1Department of Medicinal chemistry, 
Faculty of Pharmacy; 2Department of 
Medical Physics, school of Medicine; 
3Department of Pharmaceutics, 
Faculty of Pharmacy, Tehran University 
of Medical sciences, Tehran, Iran; 
4Department of hepatitis and AIDs; 
5Department of Microbiology; 
6r&D & Qc & hepatitis B & 
Nanobiotechnology Department, 
research and Production complex, 
Pasteur Institute of Iran, Tehran, Iran; 
7Department of radiology, Division 
of Nuclear Medicine, school of 
Medicine, Pennsylvania University of 
Medical sciences, Philadelphia, PA, 
UsA; 8Department of Nanomedicine, 
shahid Beheshti Medical University, 
Tehran, Iran
Correspondence: Mehdi Shafiee Ardestani  
Department of Nanobiotechnology, 
hepatitis and AIDs, Pasteur Institute of 
Iran, Tehran, Iran 
Tel/Fax +98 021 6695 3311 
email shafieeardestani@gmail.com
Background: Difficulties in the use, preparation, and cost of radioactively-labeled glyco-
sylated compounds led to this research and development study of a new gadolinium-labeled 
glucose compound that does not have a radioactive half-life or difficulties in its synthesis and 
utilization.
Methods: Based on the structure of the 2-fluoro-2-deoxy-D-glucose molecule (18FDG), 
a new compound consisting of D-glucose (1.1 nm) conjugated to a well-known chelator, 
diethylenetriamine penta-acetic acid (DTPA), was synthesized, labeled with Gd3+, and examined 
in vitro and in vivo.
Results: This novel compound not only demonstrated excellent and less costly imaging 
capability, but also showed anticancer effects on treated cells. Our results demonstrated that 
the new Gd3+-DTPA-DG compound (GDD, with GDD conjugate aggregation of about 8 nm 
at 0.02 mg/mL concentration) significantly decreased HT1080 and HT29 tumor cell numbers. 
Application of GDD to cancer cells also increased levels of tumor necrosis factor alpha, but 
did not alter blood glucose levels. Interestingly, no toxicological findings were seen in normal 
human kidney cells.
Conclusion: Dual application of GDD for both imaging and treatment of tumor cells could be 
remarkably advantageous in both the diagnosis and treatment of cancer.
Keywords: fluorodeoxyglucose, Gd3+-DTPA-DG, positron emission tomography, diagnostics, 
treatment
Introduction
Cancer is a class of diseases in which groups of cells display uncontrolled growth (divi-
sion beyond normal limits), invasion (intrusion on, and destruction of, adjacent tissues), 
and sometimes metastasis (spreading to other locations in the body via the lymph system 
or blood). These three destructive properties of cancerous tumors differentiate them 
from benign tumors, which are self-limiting, and do not invade or metastasize. Many 
cancers form a solid tumor but some, like leukemia, do not. Cancer affects people of 
all ages and was the cause of about 13% of all human deaths in 2007.1 Cancers are 
caused by abnormalities in the genetic material of transformed cells.1–3 They may be 
difficult to detect, but for some types of cancer, the earlier they are detected, the better 
the chances of effective treatment. Imaging techniques have become important in the 
early detection of many cancers. However, imaging is not simply used for detection. 
Imaging is also important for staging of the disease, determining the precise location of 
the cancer, helping to guide surgery and other cancer treatments, and checking whether 
a cancer has returned or not. Molecular imaging is a branch of medical imaging science International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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that aims to detect, localize, and monitor critical molecular 
processes in cells, tissues, and living organisms, using highly 
sensitive instrumentation and contrast mechanisms. This area 
of medical imaging has developed alongside the emergence 
of molecular medicine, in which the genetic makeup of 
each patient is factored into treatment planning. There are 
many different types of molecular imaging. Amongst them, 
positron emission tomography (PET) scans may play a role 
in determining whether or not a mass is cancerous. However, 
PET scans are more accurate in detecting larger and more 
aggressive tumors than they are in identifying tumors that 
are smaller than 8 mm and/or less aggressive. They may also 
detect cancer when other imaging techniques show normal 
results. PET scans may be helpful in evaluating and staging 
recurrent disease. They are beginning to be used to check 
whether a treatment is working, ie, whether tumor cells are 
dying and are thus using less sugar.1–3
Although conventional treatment options, such as che-
motherapy and radiation, have had many advances over the 
past few decades, cancer therapy is still far from optimal. Its 
effectiveness depends on a fine balance that is determined 
by the ability of the therapeutic agent to eradicate the tumor, 
while affecting as few healthy cells as possible. In this case, 
the systemic administration of bolus doses of powerful che-
motherapeutics often results in intense side effects due to the 
action of the drugs on sites other than the intended target.7 
With such nonspecific drug action, the concentration of the 
drug rendered available at the tumor site itself is potentially 
beneath the minimal effective concentration, putting the 
patient in the predicament of having to choose between a 
near-toxic effective dose and a comfortable ineffective dose. 
In order to alleviate this difficulty, decades of research have 
focused on developing cancer-specific drugs or delivery 
systems that can preferentially localize existing agents to 
the tumor site. Recent advances in nanotechnology promise 
further developments in target-specific drug delivery systems. 
Nanoparticles are excellent tumor-targeting vehicles because 
of the inherent properties of solid tumors.7 Due to their rapid 
growth, many solid tumors present with a fenestrated vascu-
lature and poor lymphatic drainage, resulting in an enhanced 
permeability and retention effect, which allows nanoparticles 
to accumulate specifically at the tumor site.4–7
The 2-fluoro-2-deoxy-D-glucose molecule (18FDG) is a 
1.1 nm glucose analog that is most commonly used in PET 
imaging. The fluorine in the 18FDG molecule is chosen to 
be the positron-emitting radioactive isotope, ie, fluorine-18, 
to produce 18FDG. After 18FDG is injected into a patient, a 
PET scanner can form images of the distribution of 18FDG 
around the body. The images can be assessed by a nuclear 
medicine physician or radiologist to diagnose various medi-
cal conditions.1
As a glucose analog, 18FDG is taken up by cells that use 
high amounts of glucose, such as the brain, kidney, and can-
cer cells, where phosphorylation prevents the glucose from 
being released from the cell after it has been absorbed. The 
2’-hydroxyl group in normal glucose is needed for further 
metabolism of glucose (ie, glycolysis), but 18FDG is missing 
this 2’-hydroxyl group. Thus, in common with its sister mol-
ecule, 2-deoxy-D-glucose, 18FDG cannot be further metabo-
lized in cells. This means that the 18FDG-6-phosphate formed 
when 18FDG enters the cell cannot move out of the cell before 
radioactive decay. As a result, the distribution of 18FDG is 
a good reflection of the distribution of glucose uptake and 
phosphorylation of cancerous cells in the body.1,2,7
As a result, FDG-PET can be used for diagnosis, stag-
ing, and monitoring of cancer treatment, particularly in 
Hodgkin’s disease, non-Hodgkin’s lymphoma, colorectal 
cancer, breast cancer, melanoma, and lung cancer.2 Although 
tumor metabolic imaging with 18FDG has been studied for 
more than two decades, the use of this examination in clini-
cal practice is still limited by difficult accessibility, limited 
availability, and high cost. In addition, PET radiosynthesis 
must be performed rapidly because of the short half-life of 
the positron isotopes. Chemical studies of 18FDG are usually 
complicated and involve long synthesis times (eg, one hour 
with 18FDG).3
With this in mind, Yang et al developed an alternative 
(99mTc ethylenedicysteine-deoxyglucose) to  18FDG which 
has been successfully examined in animal models, and is 
currently undergoing final multicenter clinical trials where 
it has also had some success (see Figure 1).3,4 Even though 
99mTc has some important advantages, such as a longer half-
life (six hours), lower costs, and greater availability than 18F, 
it is also radioactive and consumes charges during the imag-
ing procedure. The chemistry of 99mTc is also complicated and 
requires many intermediate conditions, such as the addition 
and/or adjustment of reducing agents, pH, and coligands.3
Magnetic resonance imaging (MRI) is a powerful and 
noninvasive diagnostic technique based on the differences 
between the relaxation rates of water protons and it provides 
important graphic images of the inside of the human body. 
MRI contrast agents, such as Gd3+-DTPA (gadopentetate 
dimeglumine, Magnevist®), improve tissue discrimination 
in MRI images.5 The most commonly used compounds for 
contrast enhancement are gadolinium-based. MRI contrast 
agents alter the relaxation times of tissues and body   cavities International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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where they are present, which, depending on the image 
weighting, can result in a higher or lower signal.5
The main disadvantages of MRI contrast agents are 
related to lower cellular uptake and nonspecific contrast 
media targeting. Thus, it would be desirable to develop a 
simple technique for labeling agents with less expensive 
paramagnetic metals, such as gadolinium, for tissue-specific 
targeted imaging, transferring the science of molecular imag-
ing from nuclear medicine to radiological science.
Most MRI contrast agents work by shortening the T1 or 
T2 relaxation time of protons located nearby. Reduction of 
the T1 relaxation time results in a hypersignal, whereas a 
reduced T2 relaxation time reduces both T2 and T2*   signals. 
The effectiveness of the contrast agent depends on its 
relaxivity (ie, its capacity to modify relaxation times). MRI 
has the advantage of having a very high spatial resolution 
and is very adept at morphological and functional imaging. 
However, MRI does have several disadvantages. First, MRI 
has a sensitivity of around 10−3–10−5 mol/L, which, compared 
with the other types of imaging, can be very limiting. This 
problem stems from the fact that the difference between 
atoms in the high energy state and the low energy state 
is very small. For example, at 1.5 Tesla, the difference 
between high and low energy states is approximately nine 
molecules per two   million. Improvements for increasing 
MRI sensitivity include hyperpolarization, by increasing 
magnetic field strength, optical pumping, and dynamic 
nuclear polarization. There are also a variety of signal 
amplification schemes based on chemical exchanges that 
increase sensitivity.3–6
Furthermore, MRI enables the acquisition of high resolution, 
three-dimensional images of the distribution of water in vivo. 
These images are enhanced by the use of contrast agents that 
catalytically decrease the relaxation time of protons in 
water in coordination, with a paramagnetic metal center. 
Gd[III], with seven unpaired electrons and a long electronic 
relaxation time, is ideally suited for such agents.   However, 
current Gd[III]-based commercial agents have very poor 
contrast enhancement capabilities due to their low relaxivity. 
  Therefore, these agents are limited to targeting sites where 
they can be expected to accumulate in high concentrations, 
such as in the bloodstream and kidneys. The current challenge 
is to design contrast agents with higher relaxivities that will 
selectively localize in specific tissues or organs. The most 
commonly used compounds for contrast enhancement are 
gadolinium-based.1–6
The present paper is the first to describe a new molecular 
gadolinium-based MRI contrast agent as an alternative to 
18FDG that has no radioactive half-life, good availability, 
reasonable costs, good anticancer effects, with fewer adverse 
effects on normal human kidneys and powerful precision in 
MRI oncology and cancer detection at the earliest stages (in 
brief, a novel bifunctional agent).
Methods
synthesis
DTPA-dianhydride
The DTPA-dianhydride synthesis procedure has been previ-
ously described. Briefly, 7.6 mmol of DTPA 3 g was dis-
solved in dimethyl sulfoxide 10 mL, acetic anhydride 20 mL, 
and pyridine 3 mL as a base under anhydrous   conditions. 
The reaction mixture was heated at 65°C for one day. 
  Subsequently, the reaction mixture was cooled, filtered, and 
washed twice in acetic anhydride and anhydrous diethyl ether. 
The residue was dried to a constant weight under vacuum 
(52 kPa) at 40°C, and a white powder was produced with a 
yield of 93% (see Figure 1).
DTPA-Dg
D-glucosamine hydrochloride was neutralized using excess 
amounts of a base, such as aqueous sodium bicarbonate.6 The reac-
tion was stirred for at least 30 minutes, then filtered, and ascorbic 
acid or sodium metabisulphite was added to the solution as an 
antioxidant agent. The solution was then immediately spray-dried 
or lyophilized, and a mild yellowish powder (D-glucosamine, 
base) was obtained, with a yield of 97% (see Figure 1).
DTPA-DA 1 mmol was dissolved in anhydrous diforma-
mide, and then N,N’-dicyclohexylcarbodiimide 1.1 mmol, 
1-hydroxy-benzotriazole 0.6 mmol, triethylamine 0.2 mL, 
and activated molecular sieve 3°A 100 mg were added to the 
medium. The reaction mixture was stirred at room tempera-
ture for at least 35 minutes. Afterwards, the reaction tempera-
ture was increased to 90–110°C, and D-deoxy-glucosamine 
(DG) 0.333 mmol was added. The reaction mixture was then 
heated (90–110°C) for 24 hours. Thin-layer chromatography 
showed only one spot and no evidence of the starting material. 
The reaction mixture was then cooled at room temperature 
(25 ± 1°C), diluted with water 0.2 mL and methanol 5 mL, 
and then filtered. A clear solution was collected, and diethyl 
ether was added one drop at a time to the solution until a 
white DTPA-monoamide (DTPA-DG) crystallized. This 
was then filtered. The above steps were repeated for further 
purification until a yellowish-orange powder was obtained. 
Alternatively, DTPA-DG was obtained from the refluxation 
of toluene/activated molecular sieve 3°A and glucosamine 
at temperatures over 90°C.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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The DTPA-DG was purified using a dialysis bag with a 
cutoff point of 500 Da in water (green chemistry) for a period 
of 24 hours. The remaining solution was removed from the 
dialysis bag and then lyophilized. A pure white powder was 
obtained with an overall yield of 40%. When ultrasonication 
was used, an overall yield of 71% was obtained.
Preparation of gDD
One mmol of DTPA-DG was reacted in water with 1 mmol 
of GdCl3 at room temperature for at least 30 minutes. The 
reaction mixture was then dialyzed using a dialysis bag 
(cutoff point 100–500 Da) and lyophilized. The yellowish 
crystalline powder was identified by ultraviolet spectroscopy 
as Gd3+-DTPA-DG (GDD). The ability of DTPA-DG to form a 
complex with Gd3 is illustrated in supplementary Figure 1.
T1/T2 measurement
The T1- and T2-weighted spin echo images at 1.5 Tesla 
(repetition time/echo time 250/16 msec and repetition time/
echo time 4000/64 msec) were analyzed qualitatively. The sig-
nal intensities of vials with contrast medium in solution and 
contrast medium in cells with the corresponding iron concen-
trations were visually compared. For quantitative data analy-
sis, the MRI images obtained were transferred as DICOM 
images to Dicom (digital imaging and communication 
in medicine) Works Software (v 1.3.5),7,8 and, for each 
concentration, three samplings and the maximum regions 
of interest were considered. Five concentrations of GDD 
(0.33, 0.17, 0.08, 0.04, and 0.02 mmol/mL) were obtained 
by dilution with sodium chloride 0.9% (Figure 2).
Figure 1 A) chemical structure of ethylenedicysteine deoxyglucose. B) general procedure for synthesis of (a) DTPA-DA and (b) DTPA-Dg.
Abbreviations: DTPA, diethylenetriamine penta-acetic acid-D-glucosamine; DTPA-Dg, diethylenetriamine penta-acetic acid-D-deoxy-glucosamine.
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All imaging protocols were performed on a 1.5 T GE 
MRI (Sigma, St Louis, MO) system. Relaxation rates of 
gadolinium-loaded complex contrast agents were measured 
at different concentrations, using different spin echo and 
gradient echo protocols. For T2 measurement, two multiecho 
spin echo protocols were used, with echo times of 12, 24, 36, 
and 48 msec and of 46, 92, 138, and 184 msec (repetition 
time 1000 msec, Equation 1):
  SignalSE = S0e−R2 
. TE  (1)
Repetition time-variable spin echo imaging (with the 
same echo time values) was used for T1 measurement. For 
T2 measurement, multiecho spin echo protocols were used, 
with repetition times of 60, 140, 240, 340, 440, 600, 800, 1000, 
1500, 2000, 3000, and 5000 msec (echo time 11 msec).
The signal intensity equation used for T1 measurement 
is shown in Equation 2.
  Signal Se SE
TR T =−
−
0 1 1 ()
/
  (2)
The T1 and T2 maps were calculated assuming Môn 
exponential signal decay. The T1 maps were calculated from 
four spin echo images, with a fixed echo time of 11 msec at 
1.5 Tesla and variable repetition times of 60, 140, 240, 340, 
440, 600, 800, 1000, 1500, 2000, 3000, and 5000 msec, using 
a nonlinear function least-square curve fitted on a pixel-by-
pixel basis. The signal intensity for each pixel as a function 
of time was expressed as follows:
Slpixel xy (t) = So(pixel xy) (1−exp (−t/T1 pixel xy)).
The T2 maps were calculated accordingly from four spin 
echo images with a fixed repetition time of 1000 msec and echo 
time values of 12, 24, 36, and 48 msec. The signal intensity for 
each pixel as a function of time was expressed as follows:
Slpixel xy (t) = So(pixel xy) exp (−t/T2 pixel xy).
Care was taken to analyze only data points with signal 
intensities significantly above the noise level. The T1 and 
T2 relaxation times (s) of the samples in the Eppendorf tubes 
were derived by region of interest measurements of the test 
samples on these T1 and T2 maps, and the results were con-
verted to R1 and R2 relaxation rates (s−1).
For this purpose, five nude mice (mean weight 
18 ± 1.2 g) bearing the human lung cancer cell line were 
used. T1 and T2 relaxation times were obtained using 
multipoint techniques, including repetition time points of 
400–3000 msec, with a constant echo time of 12 msec for 
T1 measurement and echo time points under 48 msec, with a 
constant repetition time of 2000 msec for T2   measurement, 
respectively. Coronal spin echo images (for T1 and T2 
relaxation times) were obtained with a slice thickness 
of 2.5 mm and a 0.2 mm gap, a 256 × 256 matrix size, 
a 12 × 12 field of view, a 31.2 kHz bandwidth, and two 
averages in order to reach an appropriate resolution and 
signal to noise ratio.
stability test
The GDD was dissolved in water and added to a solution 
containing 0.1 N ethylenediamine tetra-acetic acid in phos-
phate buffer and gently stirred for at least 24 hours. The 
mixture was then dialyzed, and the T1/T2 of the remaining 
solution was measured.
In vitro cell toxicity
Human fibrosarcoma epithelial-like (HT1080), human colon 
adenocarcinoma Grade II (HT29), human non-small cell lung 
cancer, human kidney proximal tubular (HKC-5) and human 
embryonic kidney 293 (HEK 293) cell lines were obtained 
from the Iran Pasteur Institute and used for cell cytotoxicity 
and inflammation response studies. The cells were grown in 
25 cm2 culture flasks using complete RPMI-1640. The cell 
culture medium was supplemented with 10% fetal bovine 
serum and 1% penicillin-streptomycin at 37°C with 5% CO2 
in an incubator. The cells were subcultured every 72 hours 
and harvested from subconfluent cultures (70% using 0.05% 
trypsin-ethylenediamine tetra-acetic acid). The cells were 
cultured at 104 cells/well in 96-well plates in all of the experi-
ments, except for the apoptosis-necrosis and tumor necrosis 
Figure 2 schematic illustration of performance of in vitro T1/T2 measurements 
using  magnetic  resonance  imaging  apparatus.  For  each  concentration,  triplicate 
sampling and the maximum region of interest were considered. Five concentrations 
of gd3+-DTPA-Dg (0.33, 0.17, 0.08, 0.04, and 0.02 mmol/mL) were obtained by 
dilution with sodium chloride 0.9%.
Abbreviation: gd3+-DTPA-Dg, gadopentetate dimeglumine-D-deoxy-glucosamine.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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factor alpha (TNF-α) secretion assays, in which 12-well 
plates at 106 cells/mL were used.
MTT assay
The MTT assay is a technique used widely for cell viability 
measurements,9 and is based on the reduction of MTT to 
formazan by viable cells. At the end of the incubation periods 
(24 and 48 hours), the supernatant of the HT1080 cells was 
removed, MTT solution was added to each well of the plates 
at a final concentration of 0.5 mg/mL GDD, and the cells were 
incubated for an additional four hours. Thereafter, the solution 
was removed, the cells were lysed, and the dye was dissolved 
in 100 µL dimethyl sulfoxide. The plates were kept in the 
dark for one hour in order to be ready for spectrophotometric 
determination. The amount of absorption in each well, reflect-
ing the conversion of MTT to formazan by the metabolically 
viable cells, was   calculated using an automated microplate 
reader at 570 nm. The results were compared with untreated 
control cultures. The same procedures were performed on 
two human kidney cell lines (incubated with concentrations 
of 0.125, 0.25, and 0.5 mg/mL GDD).
TNF-α assay
To determine if complex causes of cell death were involved 
in the initial mechanism, the amount of TNF-α secre-
tion was analyzed using a U-CyTechR enzyme-linked   
immunosorbent assay kit. After 24 hours of GDD incuba-
tion at a final concentration of 0.5 mg/mL with the HT1080 
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Figure 3A MTT results of 48 hours of gd3+-DTPA-Dg exposure to hT1080 and hT29 cell lines. The average percent of viable cells is also shown.
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cell line, the cells were pelleted, and the supernatants   
collected and used for quantitative determination of TNF-α 
secretion according to a specific protocol at 450 nm with 
a microplate reader. The negative control only contained 
complete RPMI-1640.10
Prothrombin time-activated partial 
thromboplastin time coagulation assay
Different concentrations of the complex were tested for their 
impact on coagulation processes. The prothrombin time test 
was used to investigate the extrinsic and common coagula-
tion pathways. The activated partial thromboplastin time 
assay was used to assess intrinsic and common coagulation 
pathways. In order to perform the experiments, different con-
centrations of the complex solutions in phosphate-buffered 
saline were incubated for five minutes before adding the kit 
reagents. Once the tissue thromboplastin was added to the 
anticoagulated blood samples, the times required for the for-
mation of fibrin clots were measured by visual inspection.10 
The study results were expressed in seconds and compared 
with the negative controls which only contained phosphate-
buffered saline (1:9; ie, the ratio of complex solution to the 
blood sample).
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Figure 3B MTT results of 48 hours of gd3+-DTPA-DG exposure to HKC-5 and HEK-293 human kidney cell lines. No significant toxic effect was observed.
Abbreviation: gd3+-DTPA-Dg, gadopentetate dimeglumine-D-deoxy-glucosamine.
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Figure 4 effect of gd3+-DTPA-Dg and DTPA on TNF-α release. As depicted, the 
complex increased TNF-α release significantly.
Abbreviations: DTPA, diethylenetriamine penta-acetic acid; gd3+-DTPA-Dg, 
gadopentetate dimeglumine-D-deoxy-glucosamine.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
754
Amanlou et al
Blood sample preparation
Anticoagulated blood samples (3.2% sodium citrate) 
were obtained from healthy, nonmedicated volunteers. 
  Platelet-poor plasma was isolated by centrifuging the whole 
blood at 3000 rpm for 15 minutes at room temperature. The 
blood samples were used as prepared.
Labeled gadolinium-loaded glucose at different concen-
trations was tested for its impact on the coagulation process. 
Prothrombin time was used to investigate the extrinsic and 
common coagulation pathway, while the activated partial 
thromboplastin time assay was used to assess the intrinsic and 
common coagulation pathway. In order to perform these exper-
iments, the complex solutions were incubated for five minutes 
in phosphate-buffered saline at different concentrations before 
adding the kit reagents. After tissue thromboplastin was added 
to the anticoagulated blood samples, the time required for 
forming a fibrin clot was measured by visual inspection.11 
The results were expressed in seconds and compared with the 
control, which only contained phosphate-buffered saline (1:9; 
ie, the ratio of complex solution to the blood sample).
Microscopic observations
To determine if complex causes of cell death were involved 
in the initial morphological changes after 24 hours of 
  incubation of the HT1080 cell line with GDD, changes in cell 
morphology were observed using an inverse phase-contrast 
microscope (Wilovert®, Hund Wetzlar, Wetzlar, Germany) 
and DTPA, DTPA-DG, and Magnevist® were studied in the 
control groups.
hexokinase assay
A hexokinase assay was performed to determine whether 
GDD mimics glucose phosphorylation or not. Using a ready-
made assay kit (Sigma), GDD 3.44 mg, glucose 1 mg, and 
DG 1 mg were separately dissolved in 1 mL of water. Next, 
200 µL was removed from each of the four solutions and 
diluted in 2.5 mL of water. A 10 µL aliquot of each solu-
tion was removed, mixed with 900 µL of Infinity™ glucose 
reagent (Sigma), and then incubated at 37°C for three min-
utes. The reduced form of nicotinamide adenine dinucleotide 
resulting from glucose phosphorylation showed absorption 
at 340 nm.3
Blood glucose level alterations
Various doses of DTPA-DG were intravenously injected into 
rats (six rats per group), and changes in the blood glucose 
level were determined and compared with those in the control 
groups, including insulin (glucose-lowering agent [negative 
control]), glucosamine (glucose-increasing agent [positive 
control]), and normal (the group that did not receive any 
compound),3 because when presenting a glucose moiety 
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Figure 5 Effect of DTPA-DG on blood glucose level in rats. No significant changes were observed.
Abbreviation: DTPA-Dg, diethylenetriamine penta-acetic acid-D-deoxy-glucosamine.
Table 1A Positive hexokinase enzyme response to gd3+-DTPA-
Dg, glucose, and glucosamine
Glycosylated compounds 
at same concentrations
Hexokinase activation after 
three minutes of incubation 
(340 nm)
glucose +
glucosamine +
gd3+-DTPA-Dg +
Abbreviation: gd3+-DTPA-Dg, gadopentetate dimeglumine-D-deoxy-glucosamine.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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structure in the complex it seems necessary to measure the 
changes in blood glucose by DTPA-DG.
Animals
Throughout the experiment, the nude mice were kept in 
16 × 28 × 13 cm plastic cages and the rats in stainless steel 
cages, three to six in each, maintained in a conventional 
animal room at the Pasteur Institute of Iran, which was air-
conditioned (21–22°C and 60%–70% relative   humidity) and 
ventilated 16 times/hour, and provided with an adequate 
diet and tap water ad libitum. The animal experiments 
were carried out in accordance with the recommenda-
tions of the Declaration of Helsinki and the internationally 
accepted principles for use of experimental animals, and 
they were also confirmed by the local ethics committee of 
our institution.
cancer animal model
Each animal was xenografted in the right foreleg muscle 
with 4 × l06 human non-small cell lung cancer cells. Two 
weeks after grafting, the tumors had attained a size of about 
4 mm in diameter.
MrI tumor imaging studies
The tumor-bearing animals (each group, n = 3, mean weight 
18 ± 1.3 g) were anesthetized with ketamine 50 mg/kg and 
xylazine 5 mg/kg, 0.1 mM each of GDD and Gd3+-DTPA 
(which was determined in the T1/T2 relaxivity test) was 
injected into the mice, and they were then placed in the clini-
cal MRI apparatus (1.5 Tesla, GE Sigma). The T1-weighted 
MRI procedures were performed prior to and 25 minutes 
after injection.
MrI brain studies
In order to investigate whether or not the experimental 
complex mimicked  18FDG brain pharmacokinetics, the 
above mentioned imaging procedures were performed 
20 minutes after intravenous injection for brain imag-
ing and compared with the Gd3+-DTPA control group 
(Magnevist®).
Results and discussion
size and zeta potential distribution
As can be seen in supplementary Figure 2, when the gado-
linium-loaded conjugate was formed from the DTPA-DG 
Table 1B T1 values (msec) derived from equations 1 and 2
TR Concentration Water
1/3 1/6 1/12 1/24 1/48
60 551 358 260 206 186 116
140 1035 729 468 330 251 156
240 1385 1076 764 532 394 259
340 1542 1292 971 694 520 350
440 1628 1458 1133 835 635 434
600 1705 1581 1317 1005 794 559
800 1756 1667 1478 1197 956 692
1000 1767 1684 1544 1304 1070 793
2000 1800 1767 1739 1649 1488 1212
T1 161.2643122 253.421186 420.3446826 666.2225183 916.5902841 1367.427868
1/T1 0.006201 0.003946 0.002379 0.001501 0.001091 0.0007313
r∧2 value 0.99 0.99 0.9875 0.9964 0.9971 0.9973
Table 1C T2 values (msec) derived from equations 1 and 2
TE Concentration Water
1/3  1/6 1/12 1/24 1/48
10 1762 1602 1340 1022 800 546
25 1372 1263 1097 862 711 478
40 1200 1172 1044 835 697 463
55 1043 1018 943 775 653 456
70 962 920 911 762 641 445
1/T2 0.0099 0.00883 0.00615 0.00462 0.00352 0.00305
T2 101.010101 113.25028 162.601626 216.450216 284.09 327.87
r∧2 value 0.96 0.97 0.92 0.88 0.91 0.8International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Table 1D The average corresponding Magnevist® T1 values as 
comparison standard
Magnevist 1.5 mM T1 relaxation time
1/3 178
1/6 280
1/12 433
1/24 678
1/48 924
Water 1363
Table 1E Mean gd3+-DTPA-Dg T1 values (msec) from stability 
testing. each sample was repeated at least three times
Gd3+-DTPA-DG concentration T1 relaxation time
1/3 175
1/6 275
1/12 429
1/24 677
1/48 922
Water 1363
Abbreviation: gd3+-DTPA-Dg, gadopentetate dimeglumine-D-deoxy-glucosamine.
and Gd3+, we observed a negative charge and a size of 
approximately 8 nm at a concentration of 0.02 mg/mL. 
This may have resulted from the more negative groups 
being available at its surface. These phenomena could 
result from the crosslinking of nitrogen and oxygen atoms 
with the gadolinium ion, which intercalates between three 
nitrogens of the conjugate molecule and also masks the 
negative charges (due to carboxylate ions) of the DTPA for 
the reaction with gadolinium.
MTT assay
The MTT test was performed on two cancer cell types, 
HT1080 and HT29, and also on the two human kidney cell 
lines, HEK 293 and HKC-5. The 24-hour exposure of GDD 
did not show any significant toxicity on these cell types, 
but continued exposure for 48 hours showed very signifi-
cant (P , 0.05) and powerful anticancer potency for GDD 
 ( Figure 3A). It should also be noted that the complex at 
these concentrations did not show any toxic effects on nor-
mal human kidney cells (Figure 3B). The unlabeled ligands 
(DTPA and DTPA-DG) were also demonstrated to be safe.
TNF-α assay
To investigate the initially hypothesized mechanism of the 
observed anticancer effect of GDD, a TNF-α assay was 
performed. GDD caused a significant (P , 0.05) increase 
in TNF-α release (Figure 4). This indicates the possibility 
of inflammation mediating the observed cell death as a 
potential initial mechanism.
Blood glucose levels
A nonsignificant (P . 0.05) increase in blood glucose lev-
els was observed after intravenous injections of DTPA-DG 
at various doses. The coadministration of DTPA-DG and 
insulin caused a marked decrease in blood glucose levels. 
This illustrates the effectiveness of insulin on cell/tissue 
uptake of DTPA-DG (Figure 5).
hexokinase assay
Absorption at 340 nm for GDD, DTPA-DG, D-glucose, and 
DG (Table 1A) was a sign of glucose phosphorylation due 
to the presence of the reduced form of nicotinamide adenine 
dinucleotide.
Prothrombin and activated partial  
thromboplastin times
It has been thought that GDD can have effects on blood cal-
cium and cause coagulation disorders, but the results of these 
experiments showed no significant effects (Figure 6).
Morphological changes
The number of HT1080 cancer cells was significantly reduced 
only by GDD (Figure 7) after 48 hours of exposure to the 
experimental complex. As qualitative evidence, in addition 
to the aforementioned results, the complex caused cell death 
by activation of TNF-α, although more details of this need 
to be investigated in future experiments.
T1/T2 measurement
T1 relaxivity was 62.5 mM−1 s −1 and T2 relaxivity was 
24.4 mM−1 s −1 at 37°C and 1.5 Tesla in sodium chloride 
0.9% and the r2:r1 ratio was 2.56. An important aspect of 
GDD is the low concentration required (compared with the 
0.5 mM concentration required for Magnevist) and achiev-
ing appropriate relaxivity. This is an additional benefit of the 
gadolinium-loaded complex.
The T1/T2 relaxation time results (calculated from 
equations 1 and 2) are shown in Tables 1B and 1C and 
Figures 8A and 8B (the spin echo and gradient echo 
protocol results needed to be further processed to derive 
the data in Tables 1B and 1C). GDD caused a signifi-
cant (P , 0.001) decrease in both T1 and T2 relaxation 
times compared with Magnevist (Table 1D) and water.   International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 6 Effects of the experimental complex on coagulation factors. No significant changes were observed in PT and APTT factors.
Abbreviations: PT, prothrombin time; APTT, activated partial thromboplastin time.
20 minutes after intravenous Gd3+-DTPA (Magnevist + GDD 
[Figures 9A and 9C] and Gd3+-DTPA [Figures 9A–9D]) injec-
tion in mice bearing the human lung cancer cell line were also 
obtained. As predicted, Magnevist was not capable of enhanc-
ing tumor location significantly, but due to   angiogenesis in 
the cancer cells, some enhancement as a result of Magnevist 
accumulation was observed, and an increase in MRI visibility 
was observed on coadministration of both contrast agents 
(Figures 9A–9C).
The hearts of the mice were observed after GDD injection, 
as shown in Figure 10. The gastrointestinal tract was also 
clearly enhanced when compared with controls. Additionally, 
significant enhancement of the MRI brain images was also 
obtained for GDD injection compared with Magnevist, the 
latter showing no enhancement, and this provides clear neu-
rological evidence that the pharmacokinetics of the complex 
mimic those of 18FDG (Figure 10).
The corresponding mean data for heart and brain tumor 
location in vivo T1/T2   relaxation time measurements 10 
and 20 minutes after injection of Magnevist and GDD are 
shown in Table 2.
stability test
No significant observations were found before or after 
exposure of GDD to the ethylenediamine tetra-acetic acid 
solution (Table 1E).
MrI studies
Tumor areas were found 20 minutes after GDD injection 
(an average of three mice was used for each image, see 
Figures 9A and 9B). The tumor location in the MRI images 
(T1-weighted method) 20 minutes after intravenous GDD 
injection in the mice bearing the human lung cancer cell 
line was enhanced. The MRI images (T1-weighted method) International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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As reported in the literature,  18FDG was distributed 
throughout three major parts of the body, ie, heart, tumor, and 
brain, and therefore its major applications would be in cardiol-
ogy, oncology, and neurology.1,2 As a result, it is assumed that 
GDD mimics the pharmacokinetics of 18FDG very closely.
The results show that the GDD conjugate highlighted 
tumor areas in an animal model of human lung cancer. 
Moreover, anticancer activity, phosphorylation by the 
hexokinase enzyme, and no significant alterations in blood 
glucose levels or coagulation factors, were also found for 
this complex. Furthermore, increased TNF-α release and a 
good lowering of T1/T2 potency was found. MRI contrast 
agents, such as Gd3+-DTPA, improve tissue discrimination 
in the MRI images.5,12
The findings indicate the potential possibilities of 
the GDD complex being used as an alternative to  18FDG 
in the near future. The gadolinium-loaded complex was 
  phosphorylated by the hexokinase enzyme and was proven 
to have similar cell entrance mechanisms and metabolism as 
18FDG. DTPA is classified as an extracellular fluid contrast 
agent because of its reduced uptake by cells, and this is the 
main disadvantage of the compound.12,13 To increase cellular 
uptake of DTPA (as a potential Gd3+ chelator), especially in 
cancer cells, a well recognized glucose conjugation strategy14 
was employed in this study.
When DG is conjugated to DTPA, the resulting com-
pound has the ability to enter cells and may be used to 
treat intracellular radiometal overload or, in the context 
of radiopharmaceutical labeling or MRI, has the ability 
to penetrate cancer cells. For example, the GDD complex 
may be used as a novel selective strategy in oncology for 
the diagnosis and/or treatment of tumors, thus confirming 
our hypothesis. Moreover,  18FDG and glucosamine have 
structural similarities in that they have a fluorine atom 
and an amino group at position 2 of the glucose moiety. 
DTPA-DG also has an amino group at this position in its 
glucose moiety.3,4
The molecular structure of glucosamine has several struc-
tural features, including amino, acetyl, and carboxyl groups 
at key positions that, on mediation by N-acetylglucosamine 
transferase in the nucleolemma, facilitate its entry into tumor 
cell nuclei, reflecting tumor cell proliferation. In summary, 
glucosamine is a highly attractive scaffold for a glucosyl 
ligand because the amine acts both as a potential coordina-
tion site and as a useful target for further functionalization. 
Furthermore, there is much evidence in the literature to sug-
gest that N-functionalized glucosamines show activity with 
glucose transporters and hexokinase enzymes that are most 
closely associated with the metabolism of 18FDG, even when 
the functional group is large.15,16
Finally, it should be noted that the amino-conjugating 
region of DTPA is not important, and the only important 
factor is DTPA-DG production. Hence, the difference in 
the DTPA region of conjugation to the amino compound 
does not produce any complications in its application, such 
as metal-complex formation or cell uptake.6 On the other 
hand, the binding site of the targeted amino compound is 
very important, eg, in the case of DG, where the binding 
sites are limited to carbon numbers 1 and 2 because other 
200 µm
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Figure 7 Morphological changes in hT1080 cells. A) control group without any 
treatment, B) 0.125 mg/mL gd3+-DTPA-Dg, and C) 0.5 mg/mL gd3+-DTPA-Dg. 
The amount of HT1080 cancer cells was observed to diminish significantly only in 
the gd3+-DTPA-Dg group.
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Figure 9A Magnetic resonance images (T1 weighted method) prior and 20 minutes after gd3+-DTPA-DG intravenous injection (A and B) in mice bearing human lung cancer 
(each image was performed on three mice). The tumor site was definitely enhanced. Magnetic resonance images (T1 weighted method) 20 minutes post Gd3+-DTPA + gd3+-
DTPA-Dg (C) and gd3+-DTPA (Magnevist®, D) intravenous injection in mice bearing human lung cancer.
Abbreviations: gd3+-DTPA-Dg, gadopentetate dimeglumine-D-deoxy-glucosamine; gd3+-DTPA, gadopentetate dimeglumine.
Tumor
GDD Control
Heart
Figure 9B Illustration of the whole body magnetic resonance images prior and 20 minutes post intravenous gd3+-DTPA-DG injection in mice bearing human lung cancer cells.
Abbreviation: gd3+-DTPA-Dg, gadopentetate dimeglumine-D-deoxy-glucosamine.
Table 2 Mean in vivo T1, T2 data for gd3+-DTPA-Dg and Magnevist® relaxation times at different time points and tissues are shown 
as the mean ± standard error of the mean for tumor-bearing nude mice (mean weight 18 ± 1.3 g, n = 3 in each group)
Tissue Brain  
[Gd3+-DTPA-DG]
Heart 
[Gd3+-DTPA-DG]
Tumor  
[Gd3+-DTPA-DG]
Brain  
[Magnevist]
Heart  
[Magnevist]
Tumor 
[Magnevist]
T1 (10 minutes) 365 ± 7 155 ± 9 145 ± 5 1333 ± 10 1123 ± 12 543 ± 8
T1 (20 minutes) 191 ± 4   87 ± 8 118 ± 8 1321 ± 11 1167 ± 10 442 ± 9
T2 (10 minutes) 189 ± 6   98 ± 10 102 ± 9 1002 ± 12   876 ± 13 398 ± 11
T2 (20 minutes) 101 ± 9   45 ± 7   89 ± 8   999 ± 14   882 ± 11 298 ± 7
Notes: *Decimal values are not shown; **square brackets indicate concentrations.
Abbreviation: gd3+-DTPA-Dg, gadopentetate dimeglumine-D-deoxy-glucosamine.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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carbons have an important role in cell uptake, and the metabo-
lism of hexose and conjugation at these sites may produce 
complications.17
Also, a nanosized GDD conjugate could decrease 
T1/T2 relaxation times to a significantly greater extent 
than   Magnevist. Another interesting aspect of this research 
concerns the toxic effect of the experimental complex on 
cancerous cell lines but without toxic effects on normal 
kidney cell lines at the same concentrations.
Adverse events following intravenous injection of gado-
linium contrast media are less common than for iodinated 
agents, and are estimated to occur in less than 5% of patients. 
However, acute renal failure, ie, a sudden and rapid deteriora-
tion in renal function causing failure to excrete nitrogenous 
waste products or to maintain fluid and electrolyte homeo-
stasis, may occur as a result of intravascular administration 
of radiographic and MRI contrast media.18–20
Conclusion
Contrast medium-induced nephropathy ranges in severity 
from asymptomatic, nonoliguric transient renal dysfunction 
to severe acute oliguric renal failure necessitating dialysis. 
Serum creatinine often peaks within three to four days after 
the administration of contrast media.18 Fortunately, most 
episodes of contrast medium-induced nephropathy are   
self-limiting and resolve within one to two weeks. Patients 
with contrast medium-induced nephropathy have a higher 
mortality rate (31%) than patients without contrast medium-
induced nephropathy (0.6%) after primary angioplasty 
for acute myocardial infarction.18 These side effects are 
often caused by free gadolinium uptake by kidney cells 
resulting from instability of the gadolinium complex in 
vivo.18 No significant toxicity and/or complex instability in 
vitro was observed for human kidney cell lines, and these 
are further important advantages of nanosized GDD.
There are similarities between the uptake of GDD and that 
of 18FDG in tumors, and our findings support the potential 
use of nanosized GDD conjugates as functional metabolic 
MRI agents. In addition, DTPA-DG can be easily and effi-
ciently labeled with gadolinium, in a stable and cost-effective 
manner. Given the complex mechanisms expressed in tumor 
tissue growth, this method of investigation has the potential 
to improve the diagnosis, prognosis, and planning and moni-
toring of cancer treatment.
This complex was generated and examined for the first 
time as a new MRI agent. Future experiments,  eg, investiga-
tion of caspase activation to determine the anticancer effect 
of the complex-induced cytotoxicity in cancerous cell lines 
to prove the concept of inflammation mediators or 18FDG 
comparative imaging, are needed to determine the value of 
this newly proposed alternative to 18FDG.
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Figure S1 Illustration of the original U.V spectrums of DTPA (A), D-glucosamine (B), DTPA-Dg (C), and gd3+-DTPA-Dg (D).
Supplementary materials
0
10
20
30
40
50
60
0.1 11 0 100
Size
A
I
n
t
e
n
s
i
t
y
 
(
%
)
1000 10000
0
10000
20000
30000
40000
50000
60000
70000
Zeta Potential
B
I
n
t
e
n
s
i
t
y
−200 −100 0 100 200
Figure S2 size and zeta potential distribution. A) size and B) zeta potential distribution of the DTPA-Dg compound according to concentration.